<DOC>
	<DOCNO>NCT02230059</DOCNO>
	<brief_summary>The purpose study assess treatment pattern participant metastatic castration-resistant prostate cancer ( mCRPC ) . Additionally , participant 's demographic clinical characteristic , skeletal-related event , criterion use define CRPC , prostate specific antigen ( PSA ) level pain related disease overall survival observe .</brief_summary>
	<brief_title>Study Assess Treatment Patterns Metastatic Castration-Resistance Prostate Cancer ( mCRPC )</brief_title>
	<detailed_description>This observational ( study participant identify belong study group assess biomedical health outcome ) , longitudinal ( correlational research study involve repeat observation variable long period time ) retrospective ( study look back past experience ) study describe treatment pattern mCRPC . Treatment pattern assess collect medical chart participant diagnose mCRPC prior 2009 . Primarily , percentage participant receive therapy first line treatment assess . All adverse event associate use Sponsor drug report .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma prostate Report previous surgical medical castration Castrationresistant prostate cancer ( CRPC ) diagnosis 2009 Metastatic disease document positive bone scan metastatic lesion compute tomography magnetic resonance imaging 2009 . If lymph node metastasis evidence metastasis , must 2 centimeter ( cm ) diameter Participation investigational drug device study early access programme</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Prostatic Neoplasms</keyword>
	<keyword>observational Study</keyword>
	<keyword>Metastatic castration-resistant prostate cancer</keyword>
</DOC>